The Wolverine Stack: BPC-157 + TB-500 Combined Research Protocol

The Wolverine Stack — BPC-157 and TB-500 combined — has become the most recognized repair protocol in peptide research. The name captures the idea: the fictional Wolverine heals rapidly from almost any injury. The peptide combination targets tissue repair through two complementary, largely non-overlapping mechanisms, which is why it has attracted consistent attention from researchers studying connective tissue, muscle, and systemic recovery.

Why These Two Compounds?

BPC-157 and TB-500 are not interchangeable — they work differently, at different scales, on different targets. The case for combining them is mechanistic:

BPC-157 operates locally and precisely. It upregulates VEGFR2 (promoting new blood vessel formation at the injury site), activates the FAK-paxillin signalling cascade (driving fibroblast and tenocyte migration into damaged tissue), and modulates local nitric oxide pathways. Its effects are concentrated at the site of administration.

TB-500 operates systemically. By sequestering G-actin throughout the body, it regulates cell motility at a global level — mobilizing progenitor cells from bone marrow, driving them toward injury sites via circulation, and reducing systemic inflammatory signalling. Unlike BPC-157, TB-500 can reach multiple injury sites simultaneously, including areas that are impractical to inject locally.

Together, the compounds address the three phases of tissue repair:

| Phase | BPC-157 | TB-500 |

|-------|---------|--------|

| Inflammation | Local NO modulation, cytoprotection | Systemic anti-inflammatory (TNF-α, IL-6 reduction) |

| Proliferation | Local angiogenesis, fibroblast recruitment | Systemic progenitor cell mobilization |

| Remodelling | Collagen synthesis stimulation at site | Organized matrix formation throughout body |

Research Evidence for the Combination

Individual compound research is well-established (see BPC-157 guide and TB-500 guide). Research specifically examining the combination is more limited but shows additive effects in:

• ·Achilles tendon transection models (combined treatment showed faster mechanical strength recovery than either compound alone)
• ·Muscle injury models (improved fiber regeneration and reduced fibrosis)
• ·Wound closure studies (accelerated re-epithelialization)

The combination is also the basis of the Recovery Protocol available at JA Performance — a structured research framework with documented dosing windows and endpoints.

Protocol Structure

Loading Phase (Weeks 1–4)

During the initial phase, both compounds are administered at higher frequency to establish tissue saturation and initiate the repair cascade:

BPC-157: Daily subcutaneous or intramuscular injection at or near the injury site. Systemic subcutaneous injection is an alternative when local injection is impractical.

TB-500: Two to three times per week subcutaneous injection anywhere on the body. Subcutaneous injections in the abdominal region or thigh are standard in preclinical models.

Maintenance Phase (Weeks 5–8)

Once the initial repair cascade is established:

BPC-157: Continued daily or every-other-day dosing depending on protocol design.

TB-500: Reduced to once weekly to maintain systemic progenitor cell mobilization without oversaturating the pathway.

Assessment and Rest

After the primary protocol window (typically 6–12 weeks depending on the injury type being studied), a rest period allows assessment of residual effects and prevents any potential receptor downregulation. Neither BPC-157 nor TB-500 shows significant documented tachyphylaxis, but structured rest periods are standard research practice.

Considerations for Specific Research Applications

Tendon and ligament research: BPC-157 is the primary compound; TB-500 provides systemic reinforcement. Local injection near the tendon with systemic TB-500 coverage is the standard approach in the literature.

Muscle injury research: Both compounds show direct muscle repair effects. TB-500's stem cell mobilization is particularly relevant for large-area muscle damage; BPC-157 provides localized angiogenesis.

Multi-site injury research: TB-500's systemic action makes it especially valuable when multiple anatomical sites are involved simultaneously — a scenario where local-only BPC-157 administration becomes impractical.

Cardiac research: TB-500 has a stronger preclinical dataset for cardiac tissue than BPC-157. Cardiac repair protocols often use TB-500 as the primary compound, with BPC-157 providing systemic anti-inflammatory support.

Ordering the Wolverine Stack

JA Performance offers both components individually and as a bundled Wolverine Stack with combined shipping:

• ·BPC-157 5mg — 99%+ purity, independent COA
• ·TB-500 5mg — 99%+ purity, independent COA

For full mechanistic comparison of the two compounds, see BPC-157 vs TB-500. For storage and preparation, see the peptide storage guide and reconstitution guide.

Note: All compounds are sold strictly for in vitro and laboratory research purposes. Not for human consumption.